"Receptor, IGF Type 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A protein-tyrosine kinase receptor that is closely related in structure to the INSULIN RECEPTOR. Although commonly referred to as the IGF-I receptor, it binds both IGF-I and IGF-II with high affinity. It is comprised of a tetramer of two alpha and two beta subunits which are derived from cleavage of a single precursor protein. The beta subunit contains an intrinsic tyrosine kinase domain.
| Descriptor ID |
D017526
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.185 D12.776.543.750.630.468 D12.776.543.750.750.400.780.400
|
| Concept/Terms |
Receptor, IGF Type 1- Receptor, IGF Type 1
- Receptors, IGF-1
- IGF-1 Receptors
- Receptors, IGF 1
- IGF-1 Receptor
- IGF 1 Receptor
- Receptor, IGF-1
- Receptors, Insulin-Like-Growth Factor I
- IGF-I Receptor
- IGF I Receptor
- Receptor, Insulin-Like Growth Factor Type 1
- Receptor, IGF-I
- Receptor, IGF I
- Receptor, Insulin-Like Growth Factor I
- Insulin-Like-Growth Factor I Receptor
- Insulin Like Growth Factor I Receptor
- IGF Type 1 Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptor, IGF Type 1".
Below are MeSH descriptors whose meaning is more specific than "Receptor, IGF Type 1".
This graph shows the total number of publications written about "Receptor, IGF Type 1" by people in this website by year, and whether "Receptor, IGF Type 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 1 | 2 |
| 2001 | 2 | 0 | 2 |
| 2003 | 2 | 0 | 2 |
| 2005 | 3 | 2 | 5 |
| 2006 | 1 | 1 | 2 |
| 2007 | 5 | 1 | 6 |
| 2008 | 1 | 1 | 2 |
| 2009 | 3 | 0 | 3 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 2 | 2 |
| 2013 | 2 | 1 | 3 |
| 2014 | 2 | 3 | 5 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 3 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2020 | 0 | 4 | 4 |
| 2021 | 2 | 2 | 4 |
| 2022 | 1 | 1 | 2 |
| 2024 | 1 | 2 | 3 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, IGF Type 1" by people in Profiles.
-
IGF-1 impacts neocortical interneuron connectivity in epileptic spasm generation and resolution. Neurotherapeutics. 2025 Jan; 22(1):e00477.
-
Pathways to precision medicine: deciphering the secrets of physiological and pathological atrial enlargement. Clin Sci (Lond). 2024 09 18; 138(18):1173-1177.
-
Endothelium-specific depletion of LRP1 improves glucose homeostasis through inducing osteocalcin. Nat Commun. 2021 09 06; 12(1):5296.
-
Involvement of Essential Signaling Cascades and Analysis of Gene Networks in Diabesity. Genes (Basel). 2020 10 25; 11(11).
-
Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer. Breast Cancer Res Treat. 2021 Jan; 185(1):73-84.
-
Insulin-Mediated Signaling Facilitates Resistance to PDGFR Inhibition in Proneural hPDGFB-Driven Gliomas. Mol Cancer Ther. 2017 04; 16(4):705-716.
-
Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol. 2015 Sep; 46(9):1315-22.
-
Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress. Neoplasia. 2014 Oct; 16(10):824-34.
-
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget. 2014 Oct 15; 5(19):9049-64.
-
AR collaborates with ERa in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2014 Oct; 147(3):473-85.